bluuebunny/crossref_metadata_2025_split huggingface dataset:
NQPC-1 INSIGHTS FROM PREOPERATIVE FATIGUE ASSESSMENT IN GLIOMA PATIENTS
Authors: Sakurai Takuro , Nakashima Toshihisa , Horikawa Mayumi , Shimizu Yoichi , Inamura Naoko , Sumiyoshi Ai , Matsuoka Aiko , Oki Mami , Watanabe Noriko , Okita Yusuke , Yokota Shota , Abe Risa , Ichikawa Kaneyuki , Miyakita Yasuji , Takahashi Masamichi , Ohno Makoto , Yanagisawa Shunsuke , Kawai Akira , Narita Yoshitaka 
Published: December 2022

Abstract

Introduction
Glioma is a rare type of tumor, and the research on fatigue and QOL in glioma patients is limited. Research from other countries has reported patients with intense fatigue in the preoperative stage, but no similar studies could be found in Japan. In the present study, we report a retrospective investigation of fatigue assessment performed during preoperative rehabilitation evaluation.

Participants and Methods
Participants were 90 patients admitted to the hospital for glioma surgery between January 2016 and December 2020 who underwent five specific preoperative evaluations: KPS, MMSE, Motor-Functional Independence Measure (Motor FIM), Cancer Fatigue Scale (CFS), and grip strength. Participants were divided into a CFS-High(CFS-H) group (CFS&gt;19 points) and a CFS-Low (CFS-L) group (CFS&lt;18 points), and participant attributes, MMSE, Motor FIM, and grip strength compared. Between-group comparisons used the Mann-Whitney U test.

Results
Participants were 90 patients with high-grade glioma. Fifty-seven were men, and the median age was 45 (15-81). Thirty-three participants (37%) had intense fatigue before surgery (CFS-H group: 33 participants, CFS-L group: 57 participants). In the CFS-H group and CFS-L group respectively, age was 46.5/44 (p=0.36), MMSE was 24 points/29 points (p=0.00255), Motor FIM was 89 points/91 points (p=0.0383), and grip strength was 22.2kg/25.5kg (p=0.194).

Discussion
The present study suggests that some Japanese high-grade glioma patients also experience intense fatigue before surgery. Compared to patients with low fatigue, those with high fatigue were suggested to have significant declines in cognitive function and ADL.
NQPC-5 JAPAN BRAIN TUMOR ALLIANCE: ACHIEVEMENTS IN 2021-2022 AND PATIENT VOICE
Authors: Nomura Keiko , Tagawa Hisato , Yamaguchi Shuji , Gatellier Laureline 
Published: December 2022

Abstract
Brain tumors are a major shock at diagnosis for patients and families, and their journey is impacted in various and complex ways, not only physically but mentally, financially and socially. The Japan Brain Tumor Alliance is a non-profit organization, established in 2006 to support patients and their families. As our key activity, JBTA offers patient-gathering meetings on the regular basis so that patients and families could openly share their concerns and experience. As JBTA collaborates with healthcare professionals, the up-to-date information is provided to patients and families and their needs are shared to the healthcare professionals. JBTA's achievements in 2021-2022 include the review of clinical guidelines, information-sharing events with the Japan Clinical Oncology Group and a seminar by a certified specialist regarding the social support system in Japan. With the active collaboration with other patient advocate groups, multiple petitions have been submitted to pursue further development of drugs for brain tumors. JBTA is also focusing on to provide the information to community through its website and SNS, including the stories of personal journey described by patients and families.Each of brain tumor patients and families has their own needs. Through the discussion at JBTA's monthly meetings and our online communication, they could express their real voice to the peers. JBTA picks up these issues that patients and families are facing and presents the necessity of working on their unmet needs.
NQPC-6 CHANGE ON STANDING OF HEALTH RELATED QOL IN BRAIN TUMOR AND STROKE PATIENTS ON A VOCATIONAL REHABILITATION PROGRAM
Authors: Ideguchi Makoto , Matsutani Masao , Kitamura Takayuki , Sato Akira , Ito Syoichi , Muraya Syoichi , Imaizumi Yuki , Omata Akiko 
Published: December 2022

Abstract

Introduction
It is important for brain tumor and stroke patients to evaluate not only prognosis but also health related QOL (HRQoL). In this study, we have evaluated HRQoL and reviewed the related factors to improve HRQoL through in hospital to after discharge.

Methods
One hundred-eighteen brain tumor (n=21) and stroke patients (n=97) of one hundred-thirty-one patients in our vocational rehabilitation program were enrolled. We evaluated HRQoL using EORTC QLQ-C30/BN-20 on admission, pre- and six months after discharge and examined the influence factor.

Results
In QLQ-C30 assessment on admission, although physical functioning (F), role F, social F and financial difficulties were lower than borderline, improved up to the standard healthy level by discharge. While future uncertainty score in BN-20 improved from 40points (p) to 30p, that has averaged higher value of 49p to 47p in brain tumor patients. On an individual basis, the score of 30% of global health status cases, 9% of physical F, 37% of financial F and 18% of future uncertainty deteriorated during the course of hospitalization significantly. While scores of all categories in stroke patients were improved, those of emotional F (-15.4p), social F (-14.3%), pain (+10.5p) and insomnia (+21.2p) in brain tumor patients were deteriorated, the tendency of which was especially prominent in malignant brain tumor. KPS and motor FIM in brain tumor patients correlated to physical F, and mRS and motor FIM in stroke to functioning scale strongly, to symptom scale moderately.

Conclusion
QOL evaluation can reveal the HRQoL deterioration in patients hard to detect the symptom. Appropriate intervention is needed because some cases deteriorate on an individual basis, especially brain tumor patients while HRQoL has almost improved with time. Rehabilitation therapy could contribute to HRQoL improvement because that strongly correlates to examination data of motor function.
NQPC-8 UNMET NEEDS OF CANCER PATIENTS SURVEY 2022: INTERIM ANALYSIS RESULTS
Authors: Gatellier Laureline , Majima Yoshiyuki , Moue Yuko , Charvat Hadrien , Uchitomi Yosuke , Matsuda Tomohiro 
Published: December 2022

Abstract

Background
With the recent advances in genomic medicine, the unmet needs of cancer patients (unmet needs) may be changing. A large-scale unmet needs survey was launched in 2021 with the aim of understanding the latest unmet needs and sharing information with healthcare professionals and patients, thereby contributing to the improvement of cancer treatment in Japan. The Rare Cancer Patients' Network (RCJ) is conducting this survey in collaboration with the National Cancer Centre and the National Federation of Cancer Patients' Associations (Zenganren). This presentation will report on progress since the JSNO2021 publication.

Methods
A total of 38 questions were asked in six categories: (1) detection and diagnosis; (2) treatment; (3) genomic medicine (access to genetic mutation testing); (4) clinical trials; (5) necessary information, medical care and support systems; and (6) quality of life. A combination of free-text and multiple-choice questions were asked on these, with approval obtained from the Ethics Review Committee of the National Cancer Centre at the end of October 2021 to conduct the survey online via the RCJ and the All Cancer Federation network (response deadline: 08/2022).

Results
The survey is scheduled to complete response collection and final analysis in August 2022. The results of the interim analysis will be presented at the poster session.

Conclusions
Depending on the final response collection, it may be possible to make comparisons between cancer types and identify specific patient needs in individual cancer types, such as brain tumours. At JSNO2022, we will present the results of each of the 38 questions and discuss the unmet needs of brain tumour patients with healthcare professionals, hoping that results and discussions will improve healthcare with a focus on brain tumour patients.
NQPC-9 CHARACTERIZATION AND MANAGEMENT OF DERMATOLOGIC ADVERSE EVENTS WITH OPTUNE® IN WAKAYAMA MEDICAL UNIVERSITY HOSPITAL
Authors: Fukai Junya , Seki Kohei , Sasaki Takahiro , Koyama Yoshiki , Nakao Naoyuki 
Published: December 2022

Abstract

Introduction
The NovoTTF-100A System (NovoTTF™ Therapy, Optune®, Novocure Inc.) is approved for use as a combination therapy with adjuvant temozolomide after postoperative chemo-radiation for newly diagnosed supratentorial glioblastoma (GBM). In our experience, dermatologic adverse events (dAEs) due to the continuous contact between the array and the scalp is not infrequently occurred, and we believe that the addition of skincare strategy is vital to maximize adherence to the NovoTTF™ Therapy. In Wakayama Medical University Hospital (WMUH), “WOC nurses,” certified Nurses in Wound, Ostomy and Continence Nursing, cooperate with neurosurgeons for the skincare of the patients.In this presentation, we review our dAE experience and introduce our skincare strategy by WOC nurse.

Methods
We collected and analyzed clinical information of GBM patients treated with NovoTTF™ Therapy in WHUH and focused on the dAEs of the patients.

Results
Total 7 patients (Male, 6; Female, 1). Median age, 64.4 (38-78). dAEs occurred in 6/7 cases (86%). dAEs includes contact dermatitis 5 (71%), erosion 3 (43%), ulcers 0, foliiculitis 3 (43%). CTCAE grading of dAEs, 1 or 2. Two cases (29%) abandoned NovoTTF™ Therapy due to dAEs. Based on our skincare strategy, which consists of three essential rules of scalp care (cleansing, moisturization, protection), WOC nurses have close contact with the patients and their caregivers from the beginning of the therapy.

Conclusion
The addition of skincare strategies to the NovoTTF-100A System would be vital for the adherence to NovoTTF therapy, which contribute to the therapeutic benefit of the Therapy. Not only neurosurgeons and patients but also nurses and caregivers must cooperate in scalp care and dAE treatment.
NQPC-10 IMPACT OF HEALTH-RELATED QOL (HRQOL) IN THE FIRST SIX MONTHS AFTER SURGERY ON LONG-TERM POSTOPERATIVE GENERAL HEALTH STATUS IN GLIOMA PATIENTS
Authors: Kugasawa Kazuha , Tanaka Shota , Yanagisawa Shunsuke , Takayanagi Shunsaku , Takami Hirokazu , Ohno Makoto , Takahashi Masamichi , Miyakita Yasuji , Narita Yoshitaka , Saito Nobuhito 
Published: December 2022

Abstract

Purpose
Though prolonging survival is often the focus of brain tumor therapy, evaluation of health-related quality of life (HRQoL) is important in postoperative follow-up since treatment-induced side effects or tumor-induced functional impairment could affect HRQoL.In glioma treatment, we investigated the relationship between patient-reported HRQoL assessment from 1 month preoperatively to 6 months postoperatively and overall health status at 1 year and 1.5years postoperatively.

Methods
Thirty-one glioma patients who underwent surgical treatment at our hospital and the National Cancer Center Hospital from May 2011 to August 2022 were included in this study. HRQoL and KPS were evaluated at 1 month before surgery, 6 months, 1 year and 1.5 years after surgery, respectively. The median age was 47 years, 15 (48%) were men and 16 (52%) were women. Pathological results were GBM in 19 (61%), AA in 4 (13%), AO in 2 (6%), and others in 6 (19%). The EORTC QLQ-C30/BN20 was used as a measure of HRQoL, and eligible patients answered each of the 50 questions on a 4-point scale, with scores calculated for 26 QoL status items. Bivariate analysis (Wilcoxon test) was performed on the 26 HRQoL items and KPS.

Results/Consideration
High KPS(≥70)was seen in patients who perceived themselves at 6 months postoperatively, to be “good” in the following 10 items “Physical functioning,” “Role functioning,” “Cognitive functioning,” “Global health status,” “Fatigue,” “Constipation,” “Motor dysfunction,” Communication deficit,” “Itchy skin” and “Weakness of legs. “In addition, patients who perceived their HRQoL conditions of” Sleep disturbance,”“ Future Uncertain,”and “ Bladder control”to be “good” after 6 months had a KPS of 70 or higher at 1.5 years.

Conclusions
The results suggest that long-term systemic status can also be monitored by assessing HRQoL in the first six months after surgery. Patient evaluation including sequential HRQoL is important in the treatment of glioma.
NQPC-15 DEVELOPMENT OF BRAIN TUMOR SURVIVORSHIP PROGRAM
Authors: Saito Norihiko , Hirai Nozomi , Kushida Naoki , Sato Sho , Hiramoto Yu , Fujita Satoshi , Nakayama Haruo , Hayashi Morito , Ito Keisuke , Sakurai Takatoshi , Iwabuchi Satoshi 
Published: December 2022

Abstract

Introduction
Brain tumor patients suffer from psychological distress and various sequelae from the moment they are diagnosed with a brain tumor, during and after treatment. Although the number of brain tumor survivors is increasing as a result of improved treatment outcomes for brain tumors, the support system is not sufficient. We, in collaboration with the University of California San Francisco Brain Tumor Center, have established a multidisciplinary professional staff of physicians, nurses, pharmacists, rehabilitation therapists, nutritionists, and social workers to support brain tumor patients, their families, and care givers. The brain tumor survivorship program is designed to support brain tumor patients, their families, and caregivers. This report describes their efforts.

Methods
This program started in December 2021. We asked relevant departments in the hospital to cooperate with the program. In July 2022, the “Brain Tumor Survivorship Care Program 360” website was opened to the public.

Results
As of the end of August 2022, there were 9 participants, of which 7 were patients and 2 were care givers. Of these, two were patients being treated at other hospitals. Various information is provided on the website. Web meetings are also held to provide a place where participants can communicate directly with each other. When participants were asked about their requests for the program, many of them requested information on treatment, public services, and a place for communication among patients.

Discussion
Brain tumor patients face not only life-threatening but also painful symptoms associated with the impairment of their own physical motor and cognitive functions, which they had possessed until then. Through the survivorship program, we will continue to scientifically examine and develop a support system for the various survival-related issues that brain tumor patients and their families experience from diagnosis to the end of life.
NQPC-18 THERAPEUTIC STRATEGY FOCUSING ON COGNITIVE FUNCTION AND QOL IN ELDERLY PATIENTS WITH MALIGNANT BRAIN TUMORS
Authors: Momota Hiroyuki , Saito Tsuyoshi 
Published: December 2022

Abstract

Background
Standard treatments for malignant brain tumors, such as glioblastoma (GBM) and primary CNS lymphoma (PCNSL), are recently established, except for elderly patients with neuro-cognitive impairment. We investigated our experience to adjust possible therapeutic strategy for malignant brain tumors in elderly patients according to cognitive function and QOL.

Methods
We utilized medical record data from 2015 to 2022 in our facility. Fourteen patients (11 patients with GBM and 3 with PCNSL) were retrospectively analyzed for performance status before and after surgery, neuro-cognitive function, treatments, and survival data.

Results
Median age was 76 years old, median preoperative Karnofsky performance status (KPS) was 70, median postoperative KPS was 60, and median score of mini mental state examination (MMSE) was 18/30. Several patients with GBM deteriorated on the MMSE score and KPS after surgery, and the individuals who scored &lt; 10 on the MMSE avoided radiation thrapy, while two patients with PCNSL improved on the MMSE score and KPS. Three patients with GBM and two patients with PCNSL received standard therapies. The rest of patients received alternative therapies; three patients had medical problems for receiving standard treatment, three patients avoided radiation therapy due to cognitive impairment, and three patients declined standard treatment. Median overall survival time in GBM patients was 254 days, and two patients with PCNSL have been still alive.

Conclusions
Treatments for malignant brain tumors in elderly patients are difficult, because of their comorbidities, shorter life expectancy, and cognitive impairment. On the other hand, anticancer drug therapy alone is sometimes effective and prolongs survival of those patients. Development of personalized treatment is needed focusing on cognitive function and QOL in elderly brain tumor patients.
NQPC-21 QOL EVALUATION IN THE TREATMENT COURSE OF CNS LYMPHOMA
Authors: Yamagishi Yuki , Hanayama Naomi , Sasaki Nobuyoshi , Saito Kuniaki , Kobayashi Keiichi , Nakatomi Hirofumi , Shiokawa Yoshiaki , Nagane Motoo 
Published: December 2022

Abstract

Background
Primary central nervous system lymphoma (PCNSL) is the second common primary malignant brain tumor. Compared to glioma, the treatment period is often longer, but there have been few research reports on QOL evaluation during the treatment yet. In this study, we retrospectively examined the QOL scores obtained during and following treatment of PCNSL to determine the association between changes in the QOL score and response to treatment, with particular interest in the issue in the evaluation over time.

Methods
Patients with newly-diagnosed PCNSL who were treated and evaluated for QOL by EORTC QLQ-C30/BN-20 at our facility since April 2016 were included.

Results
A total of 69 patients were included, with a median age of 69, and a male to female ratio of 41:32. The median KPS was 70, and the median MMSE score was 29 points, indicating that a majority of the patients who could undergo the testing retained adequate cognitive function. There were 38 patients (55.1%) who maintained CR during the QOL evaluation period, and their QOL function scores tended to be maintained above the baseline. In contrast, 31 patients (44.9%) who relapsed during the QOL evaluation period showed a tendency to decline in global health at the time of recurrence or evaluation immediately before recurrence, with the worsened symptom score reflecting the localization of recurrence. Any associations of changes in QOL score with therapeutic methods were identified. Changes in QOL scores were rather frequently observed with exacerbation of comorbidities, perhaps due to a high incidence of PCNSL in the elderly patients.

Conclusions
EORTC QLQ-C30/BN-20 enabled QOL evaluation that might reflect treatment effect in PCNSL. The reporting rate to the questionnaire was low in patients with substantial brain dysfunction, and QOL evaluation may also be affected by comorbidities. Further investigation of influencing factors on QOL evaluation is warranted.
ML-4 POLICY CHANGE TO PCNSL TREATMENT LED BY HEMATOLOGY, AND INITIAL TREATMENT RESULTS
Authors: Hashiba Tetsuo , Iwamura Haruka , Naito Nobuaki , Lee Kyo , Miyata Mayuko , Lee Ichi , Kamei Takamasa , Takeda Junichi , Yoshimura Kunikazu , Tenjin Hiroshi , Nonaka Masahiro , Asai Akio 
Published: December 2022

Abstract
In the treatment of PCNSL, chemotherapy is becoming the main treatment, in a while, radiation therapy is becoming to be avoided. In our hospital, hematology leads an initiative to the treatment of PCNSL from 2021. During the 7 years from 2016, there were 32 cases of PCNSL that underwent initial treatment at our hospital, of which 8 cases occurred after 2021. The breakdown was 6:2 male to female, and the average age was 71.3 years. In 5 relatively young patients, remission was induced with 5 to 6 courses of R-MPV therapy, 3 of which received high-dose chemotherapy combined with autologous peripheral blood stem cell transfusion, all of whom avoided RT and have maintained remission. In 3 older patients, only RT was performed in 1 and HD-MTX therapy was performed in 2, of which RT was combined in 1 and BSC was introduced due to treatment related sepsis in another patient. Although the follow-up period was short, there has been no recurrence except for one patient who became BSC. On the other hand, in 24 patients before 2020, HD-MTX therapy combined with RT was performed in all patients, except for 1 patient who underwent RT only due to advanced age and 1 patient who died before treatment due to poor general condition. Recurrence was observed in 8 cases, and additional RT and chemotherapy were performed. Although no recurrence was seen in 16 cases, there are only 4 patients who had been still followed up, 6 died, and 6 had unknown or BSC, with a poor prognosis. One of the reasons was thought to be related to the decrease in ADL due to radiation injury. In the absence of recurrence, ADL may be maintained long-term in young patients. On the other hand, elderly people cannot avoid RT, which is still a problem.
ML-5 THE TRANSITION OF THE TREATMENT OF 60 PCNSL CASES AT OUR INSTITUTION AND CLINICAL CONSIDERATIONS
Authors: Yoshitake Hidenobu , Negoto Tetsuya , Komaki Satoru , Nakamura Hideo , Morioka Motohiro 
Published: December 2022

Abstract
The efficacy of RMPV-A (rituximab, methotrexate, procarbazine, vincristine, and cytarabine) and whole brain irradiation for primary central nervous system lymphoma (PCNSL) have recently been reported. Our institution also introduced RMPV therapy in 2020 after an era of conventional HD-MTX to cytarabine and rituximab combination. In this report, we analyzed 60 PCNSL cases treated from 2013 to 2021.There were 32 female patients (53%) with a median age of 70 years (30-87). Five patients (8%) received radiotherapy alone as initial treatment, 30 (50%) received HD-MTX (including radiation), 17 (28%) received HD-MTX plus rituximab or cytarabine, and 9 (13%) received RMPV therapy. The response rate (CR, CRu, PR) in the HD-MTX group was 88%, and the complete response rate (CR, CRu) was 51%. In contrast, the RMPV arm had a response rate of 100% and a complete response rate of 6 patients (66.7%). 7 patients (14%) in the HD-MTX arm and 2 patients (22%) in the RMPV arm were unable to continue treatment due to adverse events. The treatment of PCNSL has undergone significant changes in recent years, with the availability of RMPV-A, thiotepa, and tirabrutinib, and it is now possible to construct treatment that avoids leukoencephalopathy caused by radiation therapy as much as possible, which had been a major problem of conventional therapy. However, because of the use of strong drugs, caution must be exercised when treating patients in poor general conditions, especially the elderly. However, the present analysis indicates that many elderly patients can be successfully treated with careful observation. In the future, it is essential to accumulate cases treated with RMPV therapy and tilabrutinib and conduct further data analysis to establish a new generation of treatment for PCNSL.